Suppr超能文献

PPAR-γ 活性的选择性调节剂:与肥胖和副作用相关的分子方面。

Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects.

机构信息

Department of Biology, Metabolex Inc., 3876 Bay Center Place, Hayward, CA 94545, USA.

出版信息

PPAR Res. 2007;2007:32696. doi: 10.1155/2007/32696.

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a key regulator of lipid metabolism and energy balance implicated in the development of insulin resistance and obesity. The identification of putative natural and synthetic ligands and activators of PPAR-gamma has helped to unravel the molecular basis of its function, including molecular details regarding ligand binding, conformational changes of the receptor, and cofactor binding, leading to the emergence of the concept of selective PPAR-gamma modulators (SPPARgammaMs). SPPARgammaMs bind in distinct manners to the ligand-binding pocket of PPAR-gamma, leading to alternative receptor conformations, differential cofactor recruitment/displacement, differential gene expression, and ultimately differential biological responses. Based on this concept, new and improved antidiabetic agents for the treatment of diabetes are in development. This review summarizes the current knowledge on the mechanism of action and biological effects of recently characterized SPPARgammaMs, including metaglidasen/halofenate, PA-082, and the angiotensin receptor antagonists, recently characterized as a new class of SPPARgammaMs.

摘要

过氧化物酶体增殖物激活受体γ(PPAR-γ)是脂质代谢和能量平衡的关键调节剂,与胰岛素抵抗和肥胖的发生有关。鉴定潜在的天然和合成的 PPAR-γ配体和激动剂有助于揭示其功能的分子基础,包括关于配体结合、受体构象变化和辅助因子结合的分子细节,从而产生了选择性 PPAR-γ调节剂(SPPARγMs)的概念。SPPARγMs 以不同的方式与 PPAR-γ的配体结合口袋结合,导致受体构象的改变,辅助因子的募集/置换的差异,基因表达的差异,最终导致生物学反应的差异。基于这一概念,正在开发新的和改进的抗糖尿病药物来治疗糖尿病。本综述总结了最近描述的 SPPARγMs 的作用机制和生物学效应的最新知识,包括 metaglidasen/halofenate、PA-082 和血管紧张素受体拮抗剂,最近被描述为一类新的 SPPARγMs。

相似文献

2
Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases.
Endocr Metab Immune Disord Drug Targets. 2006 Mar;6(1):33-43. doi: 10.2174/187153006776056620.
3
Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.
Mini Rev Med Chem. 2012 Feb;12(2):87-97. doi: 10.2174/138955712798995048.
8
Peroxisome proliferator-activated receptors as attractive antiobesity targets.
Drug News Perspect. 2004 Dec;17(10):661-9. doi: 10.1358/dnp.2004.17.10.873918.
9
Evolution of peroxisome proliferator-activated receptor agonists.
Ann Pharmacother. 2007 Jun;41(6):973-83. doi: 10.1345/aph.1K013. Epub 2007 May 22.

引用本文的文献

1
Polyphenols mediated attenuation of diabetes associated cardiovascular complications: A comprehensive review.
J Diabetes Metab Disord. 2023 Oct 18;23(1):73-99. doi: 10.1007/s40200-023-01326-x. eCollection 2024 Jun.
3
Harnessing Oleanolic Acid and Its Derivatives as Modulators of Metabolic Nuclear Receptors.
Biomolecules. 2023 Sep 28;13(10):1465. doi: 10.3390/biom13101465.
4
Naringenin and β-carotene convert human white adipocytes to a beige phenotype and elevate hormone- stimulated lipolysis.
Front Endocrinol (Lausanne). 2023 Apr 17;14:1148954. doi: 10.3389/fendo.2023.1148954. eCollection 2023.
6
The Molecular Mechanisms of Intestinal Inflammation and Fibrosis in Crohn's Disease.
Front Physiol. 2022 Feb 11;13:845078. doi: 10.3389/fphys.2022.845078. eCollection 2022.
9
The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies.
Cancers (Basel). 2020 Sep 14;12(9):2623. doi: 10.3390/cancers12092623.
10
The PPAR Pocket: Renewed Opportunities for Drug Development.
PPAR Res. 2020 Jul 1;2020:9657380. doi: 10.1155/2020/9657380. eCollection 2020.

本文引用的文献

2
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Metabolism. 2006 Sep;55(9):1159-64. doi: 10.1016/j.metabol.2006.04.013.
4
The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats.
J Pharmacol Sci. 2006 Aug;101(4):311-7. doi: 10.1254/jphs.fp0060360. Epub 2006 Aug 5.
5
KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
Biochem Pharmacol. 2006 Aug 14;72(4):446-54. doi: 10.1016/j.bcp.2006.05.005. Epub 2006 May 12.
6
Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.
Expert Opin Investig Drugs. 2006 Jul;15(7):763-78. doi: 10.1517/13543784.15.7.763.
7
Diabetic macular edema associated with glitazone use.
Retina. 2006 May-Jun;26(5):562-70. doi: 10.1097/00006982-200605000-00011.
8
Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice.
Hypertension. 2006 Jul;48(1):51-7. doi: 10.1161/01.HYP.0000225402.69580.1d. Epub 2006 May 22.
9
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
J Pharmacol Exp Ther. 2006 Aug;318(2):863-71. doi: 10.1124/jpet.106.102459. Epub 2006 May 8.
10
Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases.
Endocr Metab Immune Disord Drug Targets. 2006 Mar;6(1):33-43. doi: 10.2174/187153006776056620.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验